XMED Stock Overview
Xtrackers - MSCI Europe UCITS ETF is an exchange traded fund launched by Deutsche Asset & Wealth Management Investment S.A.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Xtrackers - MSCI Europe UCITS ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£94.74 |
52 Week High | UK£96.10 |
52 Week Low | UK£77.62 |
Beta | 0 |
1 Month Change | -0.98% |
3 Month Change | 4.52% |
1 Year Change | 8.78% |
3 Year Change | 14.34% |
5 Year Change | 41.98% |
Change since IPO | 234.42% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
XMED | GB Capital Markets | GB Market | |
---|---|---|---|
7D | 2.1% | 0.4% | 1.4% |
1Y | 8.8% | 5.8% | 1.1% |
Return vs Industry: XMED exceeded the UK Capital Markets industry which returned 5.8% over the past year.
Return vs Market: XMED exceeded the UK Market which returned 1.1% over the past year.
Price Volatility
XMED volatility | |
---|---|
XMED Average Weekly Movement | 1.5% |
Capital Markets Industry Average Movement | 4.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: XMED has not had significant price volatility in the past 3 months.
Volatility Over Time: XMED's weekly volatility (1%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | n/a | n/a | n/a |
Xtrackers - MSCI Europe UCITS ETF is an exchange traded fund launched by Deutsche Asset & Wealth Management Investment S.A. The fund is managed by State Street Global Advisors Limited. It invests in the public equity markets of developed countries in Europe.
Xtrackers - MSCI Europe UCITS ETF Fundamentals Summary
XMED fundamental statistics | |
---|---|
Market cap | US$4.28b |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs XMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XMED income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did XMED perform over the long term?
See historical performance and comparison